This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Vic Myer, PhD
President and Chief Scientific Officer at Chroma Medicine

Profile

Vic is currently the President and CSO of Chroma Medicine. Previously, he was the Chief Technology Officer at Editas Medicine and had responsibility for manufacturing and the genome editing platform.  Prior to joining Editas Medicine, Vic served as executive director and Cambridge site head for the developmental and molecular pathways department at the Novartis Institutes for Biomedical Research Incorporated (NIBR), where he also served as a research investigator, led the high-throughput biology team and oversaw the target discovery technologies platform. Vic was also a founding scientist and group leader at Akceli, Inc., a venture-backed systems-biology company focusing on commercialization of a high-throughput cell-based micro-array technology, served as senior scientist for Millennium Pharmaceuticals and held various roles at Corning, Inc. Vic received his B.S. in biology and biochemistry from Cornell University and his Ph.D. in molecular biophysics and biochemistry from Yale University.

Agenda Sessions

  • Epigenetic Editors: A New Class of Genomic Medicines

    2:00pm

Speakers at this event